Condition: Chronic Lymphocytic Leukemia · BTK Degraders · Sponsor: Nantes University Hospital
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.
This description comes directly from the study's public registry record.
ANNE LOK, Dr · 02.40.08.42.11 · anne.lok@chu-nantes.fr
Benoit Tessoulin, Dr · 02.40.08.23.96 · Benoit.tessoulin@chu-nantes.fr
Always discuss trial participation with your own doctor first.
| CHU de Angers | Angers, France | Not Yet Recruiting |
| CHU de Bordeaux | Bordeaux, France | Not Yet Recruiting |
| Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| CHU de Clermont-Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| CHD Vendée | La Roche-sur-Yon, France | Recruiting |
| Centre Léon Bernard | Lyon, France | Not Yet Recruiting |
| Institut Paoli-Calmettes (Marseille) | Marseille, France | Not Yet Recruiting |
| CHU de Montpellier | Montpellier, France | Not Yet Recruiting |
| CH Régional Universitaire de Nancy | Nancy, France | Not Yet Recruiting |
| University Hospital | Nantes, France | Recruiting |
| Hôpital Avicenne (AP-HP) | Paris, France | Not Yet Recruiting |
| Hôpital Universitaire Pitié Salpêtrière de Paris | Paris, France | Not Yet Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07099443